Benjamin Ruprecht

Benjamin Ruprecht has a diverse work experience in the field of proteomics. Benjamin most recently served as the Senior Director and Head of the Proteomics Platform at Covant Therapeutics since September 2022. Prior to that, they worked at Roivant Sciences as the Director of Translational Proteomics from October 2021 to September 2022. Benjamin was also a part of Merck, where they held the positions of Associate Principal Scientist in Chemical Biology and Discovery Proteomics from January 2020 to October 2021, and Senior Scientist in the same field from April 2017 to January 2020. Before joining Merck, they gained experience as a Postdoctoral Research Scientist at Technische Universität München from May 2016 to January 2017. Benjamin's earlier work also includes a freelance role at OmicScouts GmbH from November 2014 to February 2015.

Benjamin Ruprecht pursued a Bachelor of Science (B.Sc.) in Molecular Biotechnology/Biochemistry from the Technical University of Munich, starting in 2006 and completing it in 2009. Benjamin then went on to obtain a Master of Science (M.Sc.) in Molecular Biotechnology from the same institution, with a duration of study from 2009 to 2011. Lastly, Benjamin earned their Ph.D. in Mass spectrometry-based proteomics from the Technical University of Munich, beginning in 2012 and concluding in 2016.